SG11201408093PA - Amides of 2-amino-4-arylthiazole compounds and their salts - Google Patents

Amides of 2-amino-4-arylthiazole compounds and their salts

Info

Publication number
SG11201408093PA
SG11201408093PA SG11201408093PA SG11201408093PA SG11201408093PA SG 11201408093P A SG11201408093P A SG 11201408093PA SG 11201408093P A SG11201408093P A SG 11201408093PA SG 11201408093P A SG11201408093P A SG 11201408093PA SG 11201408093P A SG11201408093P A SG 11201408093PA
Authority
SG
Singapore
Prior art keywords
maharashtra
sector
international
mumbai
navi
Prior art date
Application number
SG11201408093PA
Other languages
English (en)
Inventor
Suresh Mahadev Kadam
Abraham Thomas
Sukumar Sinha
Sukeerthi Kumar
Bipin Parsottam Kansagra
Sachin Gavhane
Sandeep Bandu Khandagale
Shailesh Pawase
Jayant Prakashrao Patil
Shailendra Bhadane
Bhavna Mishra
Rajesh Dwivedi
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54193746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201408093P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of SG11201408093PA publication Critical patent/SG11201408093PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11201408093PA 2012-06-08 2013-06-08 Amides of 2-amino-4-arylthiazole compounds and their salts SG11201408093PA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1687MU2012 2012-06-08
US201261665282P 2012-06-27 2012-06-27
IN3519MU2012 2012-12-13
US201261748016P 2012-12-31 2012-12-31
PCT/IB2013/054703 WO2013183035A2 (en) 2012-06-08 2013-06-08 Amides of 2-amino-4-arylthiazole compounds and their salts

Publications (1)

Publication Number Publication Date
SG11201408093PA true SG11201408093PA (en) 2015-01-29

Family

ID=54193746

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408093PA SG11201408093PA (en) 2012-06-08 2013-06-08 Amides of 2-amino-4-arylthiazole compounds and their salts

Country Status (22)

Country Link
US (1) US9458173B2 (enExample)
EP (1) EP2858999B1 (enExample)
JP (1) JP5989900B2 (enExample)
KR (1) KR20150015488A (enExample)
CN (1) CN104350058A (enExample)
AP (1) AP3546A (enExample)
AU (1) AU2013273118B2 (enExample)
BR (1) BR112014029155A2 (enExample)
CA (1) CA2873570C (enExample)
CL (1) CL2014003317A1 (enExample)
EA (1) EA031334B1 (enExample)
HK (1) HK1207643A1 (enExample)
IL (1) IL236084A0 (enExample)
IN (1) IN2014MN02467A (enExample)
MX (1) MX354014B (enExample)
MY (1) MY165622A (enExample)
NZ (1) NZ701721A (enExample)
PE (1) PE20142306A1 (enExample)
PH (1) PH12014502685B1 (enExample)
SG (1) SG11201408093PA (enExample)
WO (1) WO2013183035A2 (enExample)
ZA (1) ZA201500082B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
JP6209601B2 (ja) 2012-06-08 2017-10-04 ギリアード サイエンシーズ, インコーポレイテッド フラビウイルス科ウイルスの大環状阻害剤
AU2014282762B2 (en) * 2013-06-20 2016-11-10 Ichnos Sciences SA Nanoparticulate formulation comprising a TRPA1 antagonist
EP3180345B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
WO2016042501A1 (en) * 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
TW202321229A (zh) 2021-08-18 2023-06-01 美商富曼西公司 殺真菌的取代的雜環化合物
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
WO2004014916A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
US6890923B2 (en) 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
WO2004055054A1 (en) 2002-12-18 2004-07-01 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
EP1657238A4 (en) 2003-08-22 2008-12-03 Takeda Pharmaceutical CONDENSATE PYRIMIDINE DERIVATIVE AND ITS USE
EP1713815A4 (en) 2004-02-11 2009-03-11 Smithkline Beecham Corp PTH AGONISTS
WO2005089206A2 (en) 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
WO2006083005A1 (ja) 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
WO2007019251A2 (en) 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
US20070105920A1 (en) 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
ES2436225T3 (es) * 2005-12-22 2013-12-27 Hydra Biosciences, Inc. Inhibidores TRPA1 para tratamiento del dolor
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
CN101454318A (zh) * 2006-03-22 2009-06-10 阿斯利康(瑞典)有限公司 吡啶并嘧啶衍生物及其作为pde4抑制剂的用途
JP2011201776A (ja) 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ヘテロシクリデン−n−(3,4−ジヒドロ−2(1h)−キナゾリノン−5−イル)アセトアミド誘導体
CL2008000252A1 (es) 2007-01-29 2008-03-14 Xenon Pharmaceuticals Inc Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir
EP3663295A1 (en) 2007-06-22 2020-06-10 Eli Lilly And Co. 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
WO2010004390A1 (en) * 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Quinazoline dione derivatives as trpa1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
PL2411397T3 (pl) 2009-03-23 2013-10-31 Glenmark Pharmaceuticals Sa Pochodne izotiazolo-pirymidynodionu jako modulatory TRPA1
CA2756535A1 (en) 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as trpa1 modulators
EP2411393B1 (en) 2009-03-23 2014-01-22 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as trpa1 modulators
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
EP2655377B1 (en) 2010-12-20 2016-03-30 Glenmark Pharmaceuticals S.A. 2-amino-4-arylthiazole compounds as trpa1 antagonists

Also Published As

Publication number Publication date
HK1207643A1 (en) 2016-02-05
PH12014502685A1 (en) 2015-01-26
AP2014008076A0 (en) 2014-11-30
WO2013183035A2 (en) 2013-12-12
PE20142306A1 (es) 2015-01-16
IL236084A0 (en) 2015-02-01
PH12014502685B1 (en) 2015-01-26
US20150111038A1 (en) 2015-04-23
EA201492054A1 (ru) 2016-08-31
ZA201500082B (en) 2015-12-23
CN104350058A (zh) 2015-02-11
CA2873570C (en) 2016-11-01
JP2015520183A (ja) 2015-07-16
MX354014B (es) 2018-02-08
CA2873570A1 (en) 2013-12-12
EA031334B1 (ru) 2018-12-28
IN2014MN02467A (enExample) 2015-07-10
JP5989900B2 (ja) 2016-09-07
EP2858999A2 (en) 2015-04-15
EP2858999B1 (en) 2017-05-10
CL2014003317A1 (es) 2015-02-13
MY165622A (en) 2018-04-18
BR112014029155A2 (pt) 2017-06-27
NZ701721A (en) 2016-03-31
WO2013183035A3 (en) 2014-02-27
AU2013273118A1 (en) 2014-11-27
AU2013273118B2 (en) 2015-11-05
AP3546A (en) 2016-01-14
KR20150015488A (ko) 2015-02-10
MX2014014482A (es) 2015-06-05
US9458173B2 (en) 2016-10-04

Similar Documents

Publication Publication Date Title
SG11201408093PA (en) Amides of 2-amino-4-arylthiazole compounds and their salts
SG11201808729WA (en) Bet protein degraders
SG11201407458XA (en) TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201808728QA (en) Mdm2 protein degraders
SG11201805838UA (en) Macrocyclic mcl1 inhibitors for treating cancer
SG11201407682TA (en) Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
SG11201408140QA (en) Crystalline forms of an androgen receptor modulator
SG11201809132RA (en) Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
SG11201408186TA (en) Pyridinone and pyridazinone derivatives
SG11201408133TA (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SG11201901457TA (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
SG11201408303WA (en) Adhesive compositions of propylene-based and ethylene-based polymers
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201803993XA (en) Narrow band prach with multiple tone hopping distances
SG11201407402TA (en) Carbazole-containing sulfonamides as cryptochrome modulators
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201407596TA (en) Conjugation reagents
SG11201408198QA (en) Jumper tube locking assembly and method
SG11201407988UA (en) Process for improved opioid synthesis
SG11201408297XA (en) Porous graphene oxide materials
SG11201903091VA (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors
SG11201809560QA (en) Enhancer of zeste homolog 2 inhibitors
SG11201806424TA (en) Therapeutic compounds
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch